{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:13:43Z","timestamp":1792098823987,"version":"4.4.0"},"reference-count":161,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T00:00:00Z","timestamp":1570752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Iron is vital for a vast variety of cellular processes and its homeostasis is strictly controlled and regulated. Nevertheless, disorders of iron metabolism are diverse and can be caused by insufficiency, overload or iron mal-distribution in tissues. Iron deficiency (ID) progresses to iron-deficiency anemia (IDA) after iron stores are depleted. Inflammation is of diverse etiology in anemia of chronic disease (ACD). It results in serum hypoferremia and tissue hyperferritinemia, which are caused by elevated serum hepcidin levels, and this underlies the onset of functional iron-deficiency anemia. Inflammation is also inhibitory to erythropoietin function and may directly increase hepcidin level, which influences iron metabolism. Consequently, immune responses orchestrate iron metabolism, aggravate iron sequestration and, ultimately, impair the processes of erythropoiesis. Hence, functional iron-deficiency anemia is a risk factor for several ailments, disorders and diseases. Therefore, therapeutic strategies depend on the symptoms, severity, comorbidities and the associated risk factors of anemia. Oral iron supplements can be employed to treat ID and mild anemia particularly, when gastrointestinal intolerance is minimal. Intravenous (IV) iron is the option in moderate and severe anemic conditions, for patients with compromised intestinal integrity, or when oral iron is refractory. Erythropoietin (EPO) is used to treat functional iron deficiency, and blood transfusion is restricted to refractory patients or in life-threatening emergency situations. Despite these interventions, many patients remain anemic and do not respond to conventional treatment approaches. However, various novel therapies are being developed to treat persistent anemia in patients.<\/jats:p>","DOI":"10.3390\/nu11102424","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T10:53:03Z","timestamp":1570791183000},"page":"2424","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Anemia of Inflammation with An Emphasis on Chronic Kidney Disease"],"prefix":"10.3390","volume":"11","author":[{"given":"Sajidah","family":"Begum","sequence":"first","affiliation":[{"name":"Faculty of Life Sciences and Medicine, Henriette Raphael House Guy\u2019s Campus King\u2019s College London, London SE1 1UL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0607-6909","authenticated-orcid":false,"given":"Gladys O.","family":"Latunde-Dada","sequence":"additional","affiliation":[{"name":"Department of Nutritional Sciences, School of Life Course Sciences, King\u2019s College London. Franklin-Wilkins-Building, 150 Stamford Street, London SE1 9NH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12185-008-0120-5","article-title":"Body iron metabolism and pathophysiology of iron overload","volume":"88","author":"Kohgo","year":"2008","journal-title":"Int. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.blre.2017.02.004","article-title":"New insights into iron deficiency and iron deficiency anemia","volume":"31","author":"Camaschella","year":"2017","journal-title":"Blood Rev."},{"key":"ref_3","unstructured":"GBD 2016 (2017). Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 390, 1211\u20131259."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2013-06-508325","article-title":"A systematic analysis of global anemia burden from 1990 to 2010","volume":"123","author":"Kassebaum","year":"2014","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2018-05-815944","article-title":"Iron deficiency","volume":"133","author":"Camaschella","year":"2019","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10534-012-9550-x","article-title":"Iron deficiency on neuronal function","volume":"25","author":"Munoz","year":"2012","journal-title":"Biometals: Int. J. Role Met. Ions Biol. Biochem. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2016-08-672246","article-title":"How I treat anemia in pregnancy: Iron, cobalamin, and folate","volume":"129","author":"Achebe","year":"2017","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00467-006-0381-2","article-title":"Anemia in children with chronic kidney disease","volume":"23","author":"Koshy","year":"2008","journal-title":"Pediatric Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1182\/blood-2010-05-286260","article-title":"Detection, evaluation, and management of iron-restricted erythropoiesis","volume":"116","author":"Goodnough","year":"2010","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.3748\/wjg.15.4627","article-title":"Classification of anemia for gastroenterologists","volume":"15","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1056\/NEJMra1401038","article-title":"Iron-deficiency anemia","volume":"372","author":"Camaschella","year":"2015","journal-title":"N. Eng. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/ajh.24820","article-title":"Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management","volume":"92","author":"Cappellini","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/bies.200900101","article-title":"Iron metabolism: Microbes, mouse, and man","volume":"31","year":"2009","journal-title":"BioEssays"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1182\/blood-2008-08-173641","article-title":"Contribution of STAT3 and SMAD4 pathways to the regulation of hepcidin by opposing stimuli","volume":"113","author":"Huang","year":"2009","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bcmd.2015.07.010","article-title":"Erythropoietic drive is the strongest predictor of hepcidin level in adults with sickle cell disease","volume":"55","author":"Karafin","year":"2015","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1172\/JCI0215686","article-title":"The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation","volume":"110","author":"Nicolas","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2018-06-856500","article-title":"Anemia of inflammation","volume":"133","author":"Weiss","year":"2019","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/annonc\/mds112","article-title":"Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron","volume":"23","author":"Aapro","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s12094-012-0953-5","article-title":"Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: A Spanish survey","volume":"15","author":"Steegmann","year":"2013","journal-title":"Clin. Transl. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1093\/annonc\/mdt118","article-title":"Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia","volume":"24","author":"Ludwig","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s00520-014-2189-0","article-title":"A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia","volume":"22","author":"Ludwig","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.ejca.2004.06.019","article-title":"The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients","volume":"40","author":"Ludwig","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000496967","article-title":"The Role of Intravenous Iron in the Treatment of Anemia Associated with Cancer and Chemotherapy","volume":"142","author":"Rodgers","year":"2019","journal-title":"Acta Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jacc.2004.05.070","article-title":"Anemia as a risk factor and therapeutic target in heart failure","volume":"44","author":"Felker","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1053\/j.jvca.2019.02.006","article-title":"Impact of Preoperative Iron Deficiency on Blood Transfusion in Elective Cardiac Surgery","volume":"33","author":"Hubert","year":"2019","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/eurheartj\/ehs224","article-title":"Iron deficiency and heart failure: Diagnostic dilemmas and therapeutic perspectives","volume":"34","author":"Jankowska","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/ejhf.161","article-title":"Iron deficiency in a multi-ethnic Asian population with and without heart failure: Prevalence, clinical correlates, functional significance and prognosis","volume":"16","author":"Yeo","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/ejhf.820","article-title":"Iron deficiency and red cell indices in patients with heart failure","volume":"20","author":"Tkaczyszyn","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/ejhf.837","article-title":"Iron status and inflammatory biomarkers in patients with acutely decompensated heart failure: Early in-hospital phase and 30-day follow-up","volume":"19","author":"Abraham","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11255-013-0497-9","article-title":"Ferroportin in monocytes of hemodialysis patients and its associations with hepcidin, inflammation, markers of iron status and resistance to erythropoietin","volume":"46","author":"Eleftheriadis","year":"2014","journal-title":"Int. Urol. Nephrol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1093\/ndt\/gfq321","article-title":"Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents","volume":"25","author":"Tessitore","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S0140-6736(11)61381-0","article-title":"Preoperative anaemia and postoperative outcomes in non-cardiac surgery: A retrospective cohort study","volume":"378","author":"Musallam","year":"2011","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"641876","DOI":"10.1155\/2013\/641876","article-title":"The impact of an algorithm-guided management of preoperative anemia in perioperative hemoglobin level and transfusion of major orthopedic surgery patients","volume":"2013","author":"Enko","year":"2013","journal-title":"Anemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1111\/anae.14358","article-title":"An international consensus statement on the management of postoperative anaemia after major surgical procedures","volume":"73","author":"Munoz","year":"2018","journal-title":"Anaesthesia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/tme.12476","article-title":"Cornerstones of patient blood management in surgery","volume":"28","author":"Butcher","year":"2018","journal-title":"Transfus. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/anae.13840","article-title":"Pre-operative haemoglobin levels and iron status in a large multicentre cohort of patients undergoing major elective surgery","volume":"72","author":"Munoz","year":"2017","journal-title":"Anaesthesia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000496965","article-title":"Management of Perioperative Iron Deficiency Anemia","volume":"142","author":"Bisbe","year":"2019","journal-title":"Acta Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Zhou, X., Xu, Z., Wang, Y., Sun, L., Zhou, W., and Liu, X. (2018). Association between storage age of transfused red blood cells and clinical outcomes in critically ill adults: A meta-analysis of randomized controlled trials. Med. Intensiva.","DOI":"10.1016\/j.medin.2018.07.004"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1001\/jama.2016.9185","article-title":"Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage","volume":"316","author":"Carson","year":"2016","journal-title":"JAMA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/EJA.0000000000000202","article-title":"PREPARE: The prevalence of perioperative anaemia and need for patient blood management in elective orthopaedic surgery: A multicentre, observational study","volume":"32","author":"Lasocki","year":"2015","journal-title":"Eur. J. Anaesthesiol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Nielsen, O.H., Soendergaard, C., Vikner, M.E., and Weiss, G. (2018). Rational Management of Iron-Deficiency Anaemia in Inflammatory Bowel Disease. Nutrients, 10.","DOI":"10.3390\/nu10010082"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/CEG.S43493","article-title":"Iron deficiency anemia in patients with inflammatory bowel disease","volume":"6","author":"Goldberg","year":"2013","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/apt.14920","article-title":"Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: A population-based cohort study","volume":"48","author":"Eriksson","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000443927","article-title":"Anaemia in Patients with Inflammatory Bowel Disease\u2014A Nationwide Cross-Sectional Study","volume":"93","author":"Portela","year":"2016","journal-title":"Digestion"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00004836-198806000-00014","article-title":"Quality of life in patients with inflammatory bowel disease","volume":"10","author":"Mitchell","year":"1988","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_47","unstructured":"World Health Organization, Centers for Disease Control and Prevention (2007). Assessing the Iron Status of Populations, WHO. [2nd ed.]."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1182\/blood-2005-07-3046","article-title":"The definition of anemia: What is the lower limit of normal of the blood hemoglobin concentration?","volume":"107","author":"Beutler","year":"2006","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e963","DOI":"10.1097\/MD.0000000000000963","article-title":"Management of Iron-Deficiency Anemia in Inflammatory Bowel Disease: A Systematic Review","volume":"94","author":"Nielsen","year":"2015","journal-title":"Medicine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/ecco-jcc\/jju009","article-title":"European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases","volume":"9","author":"Dignass","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_51","first-page":"113","article-title":"Anemia of chronic disease in rheumatoid arthritis and its relationship with disease activities","volume":"6","author":"Basak","year":"2013","journal-title":"Dinajpur. Med. Col."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2169\/internalmedicine.48.1578","article-title":"Circulating hepcidin in the crossroads of anemia and inflammation associated with rheumatoid arthritis","volume":"48","author":"Demirag","year":"2009","journal-title":"Intern. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/03009742.2017.1286382","article-title":"Hepcidin plasma levels are not associated with changes in haemoglobin in early rheumatoid arthritis patients","volume":"46","author":"Ostgard","year":"2017","journal-title":"Scand. J. Rheumatol."},{"key":"ref_54","first-page":"76","article-title":"Serum hepcidin level and rheumatoid arthritis disease activity","volume":"6","author":"Sahebari","year":"2018","journal-title":"Eur. J. Rheumatol."},{"key":"ref_55","first-page":"225","article-title":"Association between acute phase reactant levels, and disease activity score (DAS28), in patients with rheumatoid arthritis and anemia. Revista Rom\u00e2n\u0103 de Rheumatologie","volume":"20","author":"Gabriela","year":"2011","journal-title":"Rom. J. Rheumatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7708","DOI":"10.4081\/hr.2019.7708","article-title":"Studying anemia of chronic disease and iron deficiency in patients with rheumatoid arthritis by iron status and circulating hepcidin","volume":"11","author":"Khalaf","year":"2019","journal-title":"Hematol. Rep."},{"key":"ref_57","first-page":"286","article-title":"Extra-articular Manifestations in Rheumatoid Arthritis","volume":"5","author":"Cojocaru","year":"2010","journal-title":"Maedica"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"50s","DOI":"10.1016\/j.amjmed.2003.12.012","article-title":"Prevalence and outcomes of anemia in rheumatoid arthritis: A systematic review of the literature","volume":"116","author":"Wilson","year":"2004","journal-title":"Am. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Marti-Carvajal, A.J., Agreda-Perez, L.H., Sola, I., and Simancas-Racines, D. (2013). Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD000332.pub3"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.semarthrit.2017.08.001","article-title":"Effectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: New evidence from real-world data","volume":"47","author":"Paul","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1093\/ndt\/gfq040","article-title":"Prevalence of kidney disease in anaemia differs by GFR-estimating method: The Third National Health and Nutrition Examination Survey (1988-94)","volume":"25","author":"Estrella","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.mpmed.2007.05.008","article-title":"Anemia of chronic kidney disease","volume":"35","author":"Macdougall","year":"2007","journal-title":"Medicine"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Vera-Aviles, M., Vantana, E., Kardinasari, E., Koh, N.L., and Latunde-Dada, G.O. (2018). Protective Role of Histidine Supplementation Against Oxidative Stress Damage in the Management of Anemia of Chronic Kidney Disease. Pharmaceutical, 11.","DOI":"10.3390\/ph11040111"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1113\/jphysiol.2010.195057","article-title":"Regulation of erythropoietin production","volume":"589","author":"Jelkmann","year":"2011","journal-title":"J. Physiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00467-017-3663-y","article-title":"Anemia in chronic kidney disease","volume":"33","author":"Atkinson","year":"2018","journal-title":"Pediatric Nephrol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/ki.1993.362","article-title":"Identification of the renal erythropoietin-producing cells using transgenic mice","volume":"44","author":"Maxwell","year":"1993","journal-title":"Kidney Int."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ki.2009.460","article-title":"Hypoxia-inducible factor-2alpha-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization","volume":"77","author":"Paliege","year":"2010","journal-title":"Kidney Int."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1172\/JCI30117","article-title":"Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo","volume":"117","author":"Rankin","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1097\/01.ASN.0000017223.49823.2A","article-title":"Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys","volume":"13","author":"Rosenberger","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1073\/pnas.0608382104","article-title":"Acute postnatal ablation of Hif-2alpha results in anemia","volume":"104","author":"Gruber","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.blre.2012.12.003","article-title":"Regulation of erythropoiesis by hypoxia-inducible factors","volume":"27","author":"Haase","year":"2013","journal-title":"Blood Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cmet.2012.12.016","article-title":"Deletion of iron regulatory protein 1 causes polycythemia and pulmonary hypertension in mice through translational derepression of HIF2alpha","volume":"17","author":"Ghosh","year":"2013","journal-title":"Cell Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.cmet.2013.01.007","article-title":"The IRP1-HIF-2alpha axis coordinates iron and oxygen sensing with erythropoiesis and iron absorption","volume":"17","author":"Anderson","year":"2013","journal-title":"Cell Metab."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.molcel.2008.12.004","article-title":"Small-molecule inhibitors of HIF-2a translation link its 5\u2019UTR iron-responsive element to oxygen sensing","volume":"32","author":"Zimmer","year":"2008","journal-title":"Mol. Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.kint.2018.03.023","article-title":"Crossroads of metabolism and CKD","volume":"94","author":"Suzuki","year":"2018","journal-title":"Kidney Int."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.exphem.2015.08.010","article-title":"Kynurenine, by activating aryl hydrocarbon receptor, decreases erythropoietin and increases hepcidin production in HepG2 cells: A new mechanism for anemia of inflammation","volume":"44","author":"Eleftheriadis","year":"2016","journal-title":"Exp. Hematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/ndt\/gfx252","article-title":"The uremic toxin indoxyl sulfate interferes with iron metabolism by regulating hepcidin in chronic kidney disease","volume":"33","author":"Hamano","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.bbrc.2018.09.018","article-title":"Indoxyl glucuronide, a protein-bound uremic toxin, inhibits hypoxia-inducible factordependent erythropoietin expression through activation of aryl hydrocarbon receptor","volume":"504","author":"Asai","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_80","unstructured":"Schrier, R.W. (2007). Anemia in renal disease. Diseases of the Kidney and Urinary Tract, Lippincott Williams and Wilkins."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000486968","article-title":"Positive Iron Balance in Chronic Kidney Disease: How Much is Too Much and How to Tell?","volume":"47","author":"Wish","year":"2018","journal-title":"Am. J. Nephrol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1182\/blood-2014-12-567776","article-title":"Macrophages and iron trafficking at the birth and death of red cells","volume":"125","author":"Korolnek","year":"2015","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nrneph.2015.82","article-title":"Anaemia in kidney disease: Harnessing hypoxia responses for therapy","volume":"11","author":"Koury","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/ki.2010.217","article-title":"Erythropoietin regulates intestinal iron absorption in a rat model of chronic renal failure","volume":"78","author":"Srai","year":"2010","journal-title":"Kidney Int."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.ajkd.2009.12.030","article-title":"Molecular mechanisms of hepcidin regulation: Implications for the anemia of CKD","volume":"55","author":"Babitt","year":"2010","journal-title":"Am. J. Kidney Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/ckj\/sfv142","article-title":"Safety concerns about intravenous iron therapy in patients with chronic kidney disease","volume":"9","author":"Longhi","year":"2016","journal-title":"Clin. Kidney J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000330673","article-title":"Chronic kidney disease and risk of death from infection","volume":"34","author":"Wang","year":"2011","journal-title":"Am. J. Nephrol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"8780","DOI":"10.1073\/pnas.151179498","article-title":"Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice","volume":"98","author":"Nicolas","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1182\/blood-2002-10-3235","article-title":"Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein","volume":"101","author":"Nemeth","year":"2003","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/ndt\/gft443","article-title":"The iron cycle in chronic kidney disease (CKD): From genetics and experimental models to CKD patients","volume":"29","author":"Babitt","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2007-08-106195","article-title":"Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C\/EBPalpha","volume":"111","author":"Pinto","year":"2008","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ng.2996","article-title":"Identification of erythroferrone as an erythroid regulator of iron metabolism","volume":"46","author":"Kautz","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.1074\/jbc.M008923200","article-title":"A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload","volume":"276","author":"Pigeon","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrneph.2010.139","article-title":"Iron supplementation to treat anemia in patients with chronic kidney disease","volume":"6","author":"Besarab","year":"2010","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_96","unstructured":"National Institute for Health and Care Excellence (2015). Chronic Kidney Disease: Managing Anaemia, NICE guideline."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","article-title":"Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD","volume":"69","author":"Gupta","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"ref_98","first-page":"195","article-title":"Erythropoietin stimulating agents in the management of anemia of chronic kidney disease","volume":"2","author":"Hayat","year":"2008","journal-title":"Patient Prefer. Adherence"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"KDIGO (2012). Use of ESAs and other agents to treat anemia in CKD. Kidney Int. Sup., 2, 299\u2013310.","DOI":"10.1038\/kisup.2012.35"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3949\/ccjm.83a.15065","article-title":"Anemia of chronic kidney disease: Treat it, but not to aggressively","volume":"83","author":"Nikhoul","year":"2016","journal-title":"Clevel. Clin. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"i18","DOI":"10.1093\/ndtplus\/sfn176","article-title":"Inflammation and its impact on anaemia in chronic kidney disease: From haemoglobin variability to hyporesponsiveness","volume":"2","author":"Stenvinkel","year":"2009","journal-title":"Ndt Plus"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00467-008-1046-0","article-title":"Inflammation in chronic kidney disease: Role in the progression of renal and cardiovascular disease","volume":"24","author":"Silverstein","year":"2009","journal-title":"Pediatric Nephrol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00467-011-1832-y","article-title":"Hepcidin in anemia of chronic kidney disease: Review for the pediatric nephrologist","volume":"27","author":"Atkinson","year":"2012","journal-title":"Pediatric Nephrol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1089\/jir.1998.18.555","article-title":"Proinflammatory cytokines lowering erythropoietin production","volume":"18","author":"Jelkmann","year":"1998","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.2215\/CJN.00380111","article-title":"Endogenous erythropoietin and the association with inflammation and mortality in diabetic chronic kidney disease","volume":"6","author":"Wagner","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1681\/ASN.2006080856","article-title":"Clinical aspects of iron use in the anemia of kidney disease","volume":"18","author":"Horl","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/ndt\/gfu357","article-title":"Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: A randomized trial","volume":"30","author":"Pisani","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.3945\/jn.114.201715","article-title":"A nanoparticulate ferritin-core mimetic is well taken up by HuTu 80 duodenal cells and its absorption in mice is regulated by body iron","volume":"144","author":"Pereira","year":"2014","journal-title":"J. Nutr."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Ueda, N., and Takasawa, K. (2018). Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease. Nutrients, 10.","DOI":"10.3390\/nu10091173"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1053\/j.ajkd.2012.10.027","article-title":"Understanding iron: Promoting its safe use in patients with chronic kidney failure treated by hemodialysis","volume":"61","author":"Vaziri","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000358336","article-title":"Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: A meta-analysis","volume":"39","author":"Susantitaphong","year":"2014","journal-title":"Am. J. Nephrol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ckj\/sfx089","article-title":"Special issue: iron therapy in patients with chronic kidney disease","volume":"10","author":"Macdougall","year":"2017","journal-title":"Clincal Kidney J."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"f4822","DOI":"10.1136\/bmj.f4822","article-title":"Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: Systematic review and meta-analysis of randomised clinical trials","volume":"347","author":"Litton","year":"2013","journal-title":"BMJ"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/ki.2015.163","article-title":"A randomized trial of intravenous and oral iron in chronic kidney disease","volume":"88","author":"Agarwal","year":"2015","journal-title":"Kidney Int."},{"key":"ref_115","first-page":"F871","article-title":"Catalytic iron and acute kidney injury","volume":"311","author":"Leaf","year":"2016","journal-title":"Am. J. Physiol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.celrep.2013.11.009","article-title":"Testing the iron hypothesis in a mouse model of atherosclerosis","volume":"5","author":"Kautz","year":"2013","journal-title":"Cell Rep."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1681\/ASN.2013080838","article-title":"Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD","volume":"25","author":"Kuo","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1093\/ndt\/gfh820","article-title":"Hypersensitivity reactions and deaths associated with intravenous iron preparations","volume":"20","author":"Bailie","year":"2005","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1523-1755.2004.00872.x","article-title":"Iron sucrose in hemodialysis patients: Safety of replacement and maintenance regimens","volume":"66","author":"Aronoff","year":"2004","journal-title":"Kidney Int."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/ndt\/gfh222","article-title":"Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety","volume":"19","author":"Michael","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5414\/CN109512","article-title":"Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial","volume":"91","author":"Macdougall","year":"2019","journal-title":"Clin. Nephrol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Rostoker, G., Griuncelli, M., Loridon, C., Magna, T., Machado, G., Drahi, G., Dahan, H., Janklewicz, P., and Cohen, Y. (2015). Reassessment of Iron Biomarkers for Prediction of Dialysis Iron Overload: An MRI Study. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0132006"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Rostoker, G., Griuncelli, M., Loridon, C., Magna, T., Janklewicz, P., Drahi, G., Dahan, H., and Cohen, Y. (2014). Maximal standard dose of parenteral iron for hemodialysis patients: An MRI-based decision tree learning analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0115096"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1093\/ckj\/sfx043","article-title":"Intravenous iron therapy in patients with chronic kidney disease: Recent evidence and future directions","volume":"10","author":"Macdougall","year":"2017","journal-title":"Clin. Kidney J."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.kint.2015.10.002","article-title":"Iron management in chronic kidney disease: Conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"89","author":"Macdougall","year":"2016","journal-title":"Kidney Int."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/rheumatology\/ker223","article-title":"Risk of infections in rheumatoid arthritis patients treated with tocilizumab","volume":"51","author":"Lang","year":"2012","journal-title":"Rheumatology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/mol.112.083428","article-title":"High-throughput screening of small molecules identifies hepcidin antagonists","volume":"83","author":"Fung","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1080\/0886022X.2018.1535983","article-title":"Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease\u2014A randomized double blind crossover study","volume":"40","author":"Nowicki","year":"2018","journal-title":"Ren. Fail."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/MNH.0000000000000433","article-title":"Activin receptor ligand traps in chronic kidney disease","volume":"27","author":"Jelkmann","year":"2018","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2009-09-245977","article-title":"Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia","volume":"115","author":"Sasu","year":"2010","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Bolignano, D., D\u2019Arrigo, G., Pisano, A., and Coppolino, G. (2015). Pentoxifylline for Anemia in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134104"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1208\/s12248-010-9210-4","article-title":"Delivery of siRNA therapeutics: Barriers and carriers","volume":"12","author":"Wang","year":"2010","journal-title":"Aaps J."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bcp.13877","article-title":"Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease","volume":"85","author":"Sheetz","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients","volume":"30","author":"Besarab","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","article-title":"Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China","volume":"32","author":"Chen","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000454818","article-title":"Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects","volume":"45","author":"Akizawa","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1053\/j.ajkd.2015.11.021","article-title":"A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial","volume":"67","author":"Brigandi","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000500232","article-title":"Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study","volume":"49","author":"Parmar","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Akizawa, T., Macdougall, I.C., Berns, J.S., Yamamoto, H., Taguchi, M., Iekushi, K., and Bernhardt, T. (2019). Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease. Nephron, 1\u201312.","DOI":"10.1159\/000502012"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/978-1-4614-3209-8_35","article-title":"Hypoxia-inducible factor (HIF)\/vascular endothelial growth factor (VEGF) signaling in the retina","volume":"801","author":"Kurihara","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00467-017-3849-3","article-title":"HIF stabilizers in the management of renal anemia: From bench to bedside to pediatrics","volume":"34","author":"Kular","year":"2019","journal-title":"Pediatric Nephrol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40259-018-0278-1","article-title":"Anticalin((R)) Proteins as Therapeutic Agents in Human Diseases","volume":"32","author":"Rothe","year":"2018","journal-title":"Biodrugs"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Renders, L., Budde, K., Rosenberger, C., van Swelm, R., Swinkels, D., Dellanna, F., Feuerer, W., Wen, M., Erley, C., and Bader, B. (2019). First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0212023"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bcp.2014.09.007","article-title":"Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo","volume":"92","author":"Poli","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref_147","first-page":"316","article-title":"High Sulfation and a High Molecular Weight Are Important for Anti-hepcidin Activity of Heparin","volume":"6","author":"Asperti","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_148","first-page":"564","article-title":"Vitamin D as a New Regulator of Iron Metabolism: Vitamin D Suppresses Hepcidin in Vitro and In Vivo","volume":"22","author":"Bacchetta","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_149","first-page":"19","article-title":"The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes","volume":"1","author":"Zughaier","year":"2014","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Panwar, B., McCann, D., Olbina, G., Westerman, M., and Gutierrez, O.M. (2018). Effect of calcitriol on serum hepcidin in individuals with chronic kidney disease: A randomized controlled trial. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-0823-7"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Braithwaite, V.S., Crozier, S.R., D\u2019Angelo, S., Prentice, A., Cooper, C., Harvey, N.C., and Jones, K.S. (2019). The Effect of Vitamin D Supplementation on Hepcidin, Iron Status, and Inflammation in Pregnant Women in the United Kingdom. Nutrients, 11.","DOI":"10.3390\/nu11010190"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Edmonston, D., and Wolf, M. (2019). FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nat. Rev. Nephrol.","DOI":"10.1038\/s41581-019-0189-5"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Hanudel, M.R., Eisenga, M.F., Rappaport, M., Chua, K., Qiao, B., Jung, G., Gabayan, V., Gales, B., Ramos, G., and de Jong, M.A. (2018). Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. Nephrol. Dial. Transplant.","DOI":"10.1093\/ndt\/gfy189"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s11914-018-0492-2","article-title":"Non-renal-Related Mechanisms of FGF23 Pathophysiology","volume":"16","author":"Hanudel","year":"2018","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ki.2015.290","article-title":"Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production","volume":"89","author":"David","year":"2016","journal-title":"Kidney Int."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.kint.2016.05.019","article-title":"Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease","volume":"90","author":"Singh","year":"2016","journal-title":"Kidney Int."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1096\/fj.201700667R","article-title":"Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia","volume":"32","author":"Agoro","year":"2018","journal-title":"Faseb J."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1182\/blood-2010-03-271791","article-title":"Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease","volume":"116","author":"Song","year":"2010","journal-title":"Blood"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/bph.14143","article-title":"Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey","volume":"175","author":"Hohlbaum","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/ng.335","article-title":"BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism","volume":"41","author":"Andriopoulos","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/blood-2010-06-289082","article-title":"Heparin: A potent inhibitor of hepcidin expression in vitro and in vivo","volume":"117","author":"Poli","year":"2011","journal-title":"Blood"}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/11\/10\/2424\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:25:12Z","timestamp":1760189112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/11\/10\/2424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,11]]},"references-count":161,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10]]}},"alternative-id":["nu11102424"],"URL":"https:\/\/doi.org\/10.3390\/nu11102424","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,11]]}}}